Do AstraZeneca plc, Marks and Spencer Group Plc or Vodafone Group plc Have The Best Income Potential?

Income seekers can’t afford to overlook AstraZeneca plc (LON: AZN), Marks and Spencer Group Plc (LON: MKS) and Vodafone Group plc (LON: VOD), says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Income seekers have been shaken by the number of FTSE 100 companies slashing their dividends or dropping them altogether over the past year, but don’t despair, there are more solid income options out there.

AstraZeneca

Pharmaceuticals giant AstraZeneca (LSE: AZN) is all too often overshadowed by rival GlaxoSmithKline and their dividend disparity is perhaps the main culprit. Glaxo has offered more generous income payouts in recent years but the gap has narrowed, with AstraZeneca now yielding 4.65% against Glaxo’s 5.47%. When it comes to capital growth, AstraZeneca has been the clear winner, returning 39% over five years, roughly double Glaxo’s 19%.

AstraZeneca isn’t exactly flying right now. Full-year revenue growth was just 1% at constant exchange rates. But these are transitional times, as it faces up to patent expiry for its lucrative Crestor treatment in the US, while chief executive Pascal Soriot crosses his fingers and hopes heavy investment in its future drugs pipeline bears fruit. R&D costs rose 21% last year as he looks to hit his $45bn revenue target for 2023, up from $26bn last year.

There are promising signs, with a 44% rise in sales of Brilinta/Brilique, 26% in diabetes treatment, including 76% growth in emerging markets. The downside is that investors face a forecast 7% drop in earnings per share (EPS) and flat growth in 2017 while they wait to see if Soriot can deliver blockbuster success. That will ultimately determine the fate of both dividend and share price growth. Fingers crossed!

Marks & Spencer Group

It has been a tough year for investors in Marks & Spencer Group (LSE: MKS), with the share price down 17%. At least that makes the valuation more tempting at 12.35 times earnings, while the yield is now 4.4%. I was impressed by outgoing chief executive Mark Bolland’s brave decision to shun the Christmas discounting frenzy, and even more impressed when I saw the boost it gave gross margins. Bolland steps down in April and his failure to turn around the clothing division will cast a shadow over his six-year tenure.

This is still a company of mismatched separates, with food sales flying while clothing continues to sag. M&S has shown the supermarkets how to do it, while just about every other clothing retailer has taught it a harsh lesson in return. Now we wait to see whether Bolland’s internally-promoted successor Steve Rowe can finally restore M&S’s fashion sense. The dividend at least looks sound.

Vodafone Group

Telecoms giant Vodafone Group (LSE: VOD) has leapt 10% in a month, helped by February’s healthy Q3 results showing a sixth consecutive quarter of growing service revenues. South Africa was the star, with service revenues up 7.2%, while the Middle East and Asia also put on a show. Europe was a mixed bag as Vodafone fought back from recent reverses, but it did add more than 311,000 broadband customers and 506,000 mobile contracts in Q3.

Group chief executive Vittorio Colao said its hefty investment in 4G and fibre is now paying off with strong growth in data usage. Much now depends on whether Europe can recover before central bank president Mario Draghi runs out of ammunition. Forecast EPS growth of 28% this year and 23% next looks hopeful. The 5.11% dividend yield is tempting and safe for now, just note that cover has fallen to a lowly 0.5.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »